Statin Selection and Dosing for Hyperlipidemia
For most patients with hyperlipidemia requiring statin therapy, initiate atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily as high-intensity statin therapy to achieve an LDL cholesterol reduction of ≥50% from baseline. 1, 2
Risk-Based Statin Intensity Selection
The choice of statin intensity depends on your patient's cardiovascular risk category:
Very High-Risk Patients (Target LDL-C <70 mg/dL or <1.8 mmol/L)
- Patients with established atherosclerotic cardiovascular disease: Start high-intensity statin therapy immediately 3
- Acute coronary syndrome: Initiate or continue high-dose statins early after admission regardless of baseline LDL-C 3
- Diabetes with multiple ASCVD risk factors: Use high-intensity statin to reduce LDL-C by ≥50% and target LDL-C <70 mg/dL 1, 2
- Peripheral arterial disease or history of non-cardioembolic stroke: High-intensity statin therapy is recommended 3
High-Risk Patients (Target LDL-C <100 mg/dL or <2.6 mmol/L)
- Diabetes aged 40-75 years with additional ASCVD risk factors: High-intensity statin therapy 1
- Type 2 diabetes with CVD, CKD, or age >40 with risk factors: Target LDL-C <100 mg/dL 3
Moderate-Risk Patients
- Diabetes aged 40-75 years without additional risk factors: Moderate-intensity statin therapy 1
- Diabetes aged 20-39 years with additional risk factors: Consider initiating statin therapy 1
Specific Statin and Dose Recommendations
High-Intensity Statin Options (≥50% LDL-C reduction):
Moderate-Intensity Statin Options (30-49% LDL-C reduction):
- Atorvastatin 10-20 mg daily 1
- Rosuvastatin 5-10 mg daily 1
- Simvastatin 20-40 mg daily (avoid 80 mg due to myopathy risk) 1, 2
- Pravastatin 40-80 mg daily 1
Special Populations
HIV-Infected Patients on Antiretroviral Therapy
- For elevated LDL-C: Pravastatin 20-40 mg daily (starting dose) or atorvastatin 10 mg daily (starting dose) with careful monitoring 8
- Fluvastatin 20-40 mg daily is a reasonable alternative 8
- Avoid high-dose statins initially due to drug-drug interaction concerns with protease inhibitors 8
Familial Hypercholesterolemia
- Intense-dose statin therapy, often combined with ezetimibe 3
Chronic Kidney Disease (Stage 3-5, non-dialysis)
- Statins or statin/ezetimibe combination indicated 3
- Do not initiate statins in dialysis-dependent patients without atherosclerotic CVD 3
Elderly Patients (>75 years)
- Continue statin therapy if already on treatment 1
- Consider initiating moderate-intensity statin after discussing benefits and risks 1
Monitoring and Dose Titration
- Recheck lipid panel 4-8 weeks after initiating therapy to assess response 2, 4
- If LDL-C remains ≥70 mg/dL on maximally tolerated high-intensity statin: Add ezetimibe or PCSK9 inhibitor 1, 2
- Once goals achieved: Monitor lipid panel every 6-12 months 9
- Monitor for statin-associated muscle symptoms and check liver function tests if clinically indicated 2
Common Pitfalls to Avoid
- Do not start with low-dose statins in high-risk patients requiring ≥50% LDL-C reduction – initiate high-intensity therapy from the outset 2, 4
- Avoid simvastatin 80 mg due to increased myopathy risk 1, 2
- Do not use statins as first-line therapy for isolated severe hypertriglyceridemia (>500 mg/dL) – use fibrates instead 8
- In HIV patients on protease inhibitors: Exercise caution with statin selection and dosing due to drug interactions 8
- Maximum tolerated statin dose should be used if patients cannot tolerate intended intensity 1
Combination Therapy Considerations
If LDL-C or non-HDL-C goals are not met with maximum statin doses:
- Add ezetimibe as first-line combination agent 1, 2
- Consider PCSK9 inhibitor if goals still not achieved 1, 2
- Fibrate addition can be considered but use with great caution due to myopathy risk, particularly with gemfibrozil 8, 9
- Pravastatin or fenofibrate combinations appear safer than gemfibrozil-statin combinations 8